COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06372457
Status
Active Not Recruiting

Conditions

  • Hypertrophic Cardiomyopathy (HCM)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Approved Hypertrophic Cardiomyopathy drug treatments — DRUG
    As per product label
  • Mavacamten — DRUG
    As per product label

Study Details

COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.

Key Dates

Start date
Dec 1, 2023
Status verified
Apr 2026
Primary completion
Sep 29, 2025
Completion
Jun 30, 2026

Study Design

Enrollment
331 participants (actual)

Arms

  • Arm: Participants with Hypertrophic Cardiomyopathy (HCM)
    Participants with an available HCM diagnosis date and without evidence of an HCM phenocopy
  • Arm: Participants treated with mavacamten.

Primary Outcome Measure

Participant age at Hypertrophic Cardiomyopathy (HCM) diagnosis [ Time Frame: Baseline, index date ]

Locations (1)

FacilityCityStateZIPSite coordinators
IQVIADurhamNorth Carolina27703-

Find similar trials in Durham, NC

By research site
IQVIA· Durham, NC

Related Studies